rivipansel   Click here for help

GtoPdb Ligand ID: 8307

Synonyms: GMI-1070 | PF-06460031 | PF-0646003102
Compound class: Synthetic organic
Comment: Rivipansel is a synthetic glycomimetic molecule, rationally designed as a pan-selectin inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 35
Hydrogen bond donors 15
Rotatable bonds 34
Topological polar surface area 599.73
Molecular weight 1446.36
XLogP -2.39
No. Lipinski's rules broken 3
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCC1OC(OC2CC(CC(C2OC2OC(C)C(C(C2O)O)O)NC(=O)c2cc(=O)[nH]c(=O)[nH]2)C(=O)NCCNC(=O)COCCOCC(=O)Nc2cc(cc3c2c(cc(c3)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)C(C(C1O)OC(C(=O)O)CC1CCCCC1)OC(=O)c1ccccc1
Isomeric SMILES OC[C@H]1O[C@@H](O[C@@H]2C[C@@H](C[C@@H]([C@H]2O[C@@H]2O[C@@H](C)[C@H]([C@H]([C@@H]2O)O)O)NC(=O)c2cc(=O)[nH]c(=O)[nH]2)C(=O)NCCNC(=O)COCCOCC(=O)Nc2cc(cc3c2c(cc(c3)S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)O)[C@@H]([C@H]([C@H]1O)O[C@H](C(=O)O)CC1CCCCC1)OC(=O)c1ccccc1
InChI InChI=1S/C58H74N6O31S3/c1-27-45(69)47(71)48(72)56(90-27)95-49-35(62-53(74)36-23-41(66)64-58(78)63-36)19-31(20-37(49)92-57-51(94-55(77)29-10-6-3-7-11-29)50(46(70)39(24-65)93-57)91-38(54(75)76)16-28-8-4-2-5-9-28)52(73)60-13-12-59-42(67)25-88-14-15-89-26-43(68)61-34-21-32(96(79,80)81)17-30-18-33(97(82,83)84)22-40(44(30)34)98(85,86)87/h3,6-7,10-11,17-18,21-23,27-28,31,35,37-39,45-51,56-57,65,69-72H,2,4-5,8-9,12-16,19-20,24-26H2,1H3,(H,59,67)(H,60,73)(H,61,68)(H,62,74)(H,75,76)(H,79,80,81)(H,82,83,84)(H,85,86,87)(H2,63,64,66,78)/t27-,31+,35-,37+,38-,39+,45+,46-,47+,48-,49+,50-,51+,56-,57+/m0/s1
InChI Key VXBNTHRZPJLRSS-PTCSXESPSA-N
No information available.
Summary of Clinical Use Click here for help
Rivipansel is being assessed in a Phase 3 clinical trial as a potential therapy for vaso-occlusive crisis (VOC) in hospitalized patients with sickle cell disease.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The selectins (E-selectin, L-selectin and P-selectin) are glycoprotein cell adhesion molecules implicated in inflammatory processes such as leukocyte adhesion which play a key role in VOC in sickle cell disease. Transgenic mice lacking both P- and E-selectins are protected from VOC [2], indicating the potential of these molecules for pharmaceutical inhibition. Phase II clinical trial with rivipansel in these patients sighnificantly decreased the time it took for the VOC to resolve. Rivipansel has been granted FDA orphan drug and fast track status for VOC, as the drug appears to benefit an as yet, unmet clinical need.